When was Ambion founded?

Ambion was founded in 1988 and raised its 1st funding round 15 years after it was founded.

Where is Ambion located?

Ambion is headquartered in Austin, United States.

How many employees does Ambion have?

As of Aug 31, 2026, the latest employee count at Ambion is 37.

Is Ambion a funded company?

Ambion is a funded company, having raised a total of $10.5M across 6 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on May 02, 2003.

When was the latest funding round of Ambion?

Ambion's latest funding was a $***** Grant (prize money) round on Mar 25, 2010, with participation from 1 investor.

Where does Ambion rank among its competitors?

Ambion ranks 116th amongst 492 active competitors, of which 64 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sebia, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Ambion?

Ambion's top competitors include Qiagen, Enzo and Parse Biosciences. Among them, Sebia secured the most recent funding round in May, 2026.

Ambion - 2026 Company Profile, Funding & Competitors

Ambion is an early stage company based in Austin (United States), founded in 1988. It operates as a Provider of RNA extraction reagents and products. Ambion has raised $10.5M in funding. The company has 492 active competitors, including 64 funded and 72 that have exited. Its top competitors include companies like Qiagen, Enzo and Parse Biosciences.

Company Details

Provider of RNA extraction reagents and products. The products of the company include RNA extraction kits and RNA isolation reagents, single cell-to-CT kit for qRT-PCR, DNA & RNA purification & analysis equipment, and many more.

Website: ambion.com
Part Of

Key Metrics

Founded Year

1988

Location

Austin, United States

Stage

Early Stage

Total Funding

$10.5M in 6 rounds

Latest Funding Round

Grant (prize money), Mar 25, 2010, $*****

Investors

Telegraph Hill Partners & 1 more

Ranked

116^th among 492 active competitors

Employee Count

37 as on Aug 31, 2026

Similar Companies

Qiagen & 262 more

View Ambion's full profile

Ambion has raised a total funding of $10.5M over 6 rounds. Its first funding round was on May 02, 2003. Its latest funding round was a Grant (prize money) round on Mar 25, 2010 for $*****. 1 investor participated in its latest round. Ambion has 2 institutional investors.

Here is the list of recent funding rounds of Ambion:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 25, 2010	3978460	Grant (prize money)	1060835	9842854	3864974	3676175
Jul 24, 2009	8036042	Grant (prize money)	2761856	8113487	2396086	HHS
Jun 16, 2009	7773336	Grant (prize money)	3687821	8060978	8473271	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Ambion's funding rounds and investors

Ambion's employee count trend

Ambion has 37 employees as of Aug 26. Here is Ambion's employee count trend over the years:

Uncover Ambion's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ambion include Qiagen, Enzo and Parse Biosciences. Here is the list of Top 10 competitors of Ambion, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Qiagen 1984, Venlo (Netherlands), Acquired	Provider of products and reagents for molecular diagnostic assays	-	Life Sciences Partners, Harmonic & 6 others	65/100
2nd	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	65/100
3rd	Parse Biosciences 2018, Seattle (United States), Series C	Developer of RNA-sequencing solution-based transcriptome kit to analyze health data	$100M	Marshall Wace, Janus Henderson Investors & 8 others	64/100
4th	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	63/100
5th	Devyser 2004, Stockholm (Sweden), Public	Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders	$15.5M	Swedbank Robur, Fjarde AP-fonden & 1 others	61/100
6th	Miltenyi Biotec 1989, Bergisch Gladbach (Germany), Funding Raised	Develops tools and products for research and clinical application	-	Europa, HHS	58/100
7th	RareCyte 2009, Seattle (United States), Series C	Developer of technologies for the analysis of rare and single cells in the blood	$114M	Arboretum Ventures, Health Quest Capital ... & 11 others	57/100
8th	Neogen 1982, Lansing (United States), Acquired	Solutions for food and animal safety, diagnostics, and genomics	$700K	Innovative Ventures, NISA	56/100
9th	Sebia 1967, Evry Courcouronnes (France), Acquired	Developer of electrophoresis-based in vitro diagnostics products	-	Warburg Pincus, HarbourVest Partners & 5 others	56/100
10th	BioIVT 1981, Westbury (United States), Acquired	Provider of in vitro diagnostic products and assay services	-	WILsquare Capital, Europa & 4 others	56/100
116th	Ambion 1988, Austin (United States), Early Stage	Provider of RNA extraction reagents and products	$10.5M	Telegraph Hill Partners, HHS	31/100